2026年 業績

＜論文＞

1. Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
   Shiozaki M, Minagawa T, Yokoyama H, Hirotsu Y, Oyama T, Omata M, Akiyama Y.
   Int J Urol. 2026;33(1):e70293.
2. Performance evaluation of the Elecsys® HCV Duo immunoassay for hepatitis C virus through simultaneous antibody and core antigen detection
   Sugiura H , Hiraga S , Hirotsu Y , Omata M
   Journal of Clinical Virology Plus. 2026;6(3):100261
3. Paired tumor-normal targeted sequencing supports clonal independence of multiple primary malignancies in patients with gastrointestinal stromal tumors.
   Asakawa Y, Hirotsu Y, Omata M.
   Int J Clin Oncol. in press
4. Presubmission Pathologic Quality Control for FoundationOne CDx Comprehensive Genomic Profiling.
   Natori Y, Hirotsu Y, Shibusawa M, Nakamura K, Watanabe S, Amemiya S, Nagakubo Y, Tajiri R, Oyama T, Mochizuki H, Omata M.
   J Mol Diagn. 2026:S1525-1578(26)00174-1